43
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A Systematic Review and Meta-analysis of trials.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          PD-1/PD-L1 inhibitors show significant clinical activity in non-small cell lung carcinoma (NSCLC). However, they are often associated with potentially fatal immune mediated pneumonitis. Preliminary reports of trials suggest a difference in the rate of pneumonitis with PD-1 and PD-L1 inhibitors. We sought to determine the overall incidence of pneumonitis, and differences according to type of inhibitors and prior chemotherapy use.

          Related collections

          Author and article information

          Journal
          Chest
          Chest
          Elsevier BV
          1931-3543
          0012-3692
          May 09 2017
          Affiliations
          [1 ] Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio.
          [2 ] Department of Biostatistics, Case Western Reserve University, Cleveland, Ohio.
          [3 ] Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, School of Pharmacy, University of Connecticut, Storrs, Connecticut.
          [4 ] Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.
          [5 ] Department of Hematology and Oncology, Tausig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
          [6 ] Department of Hematology and Oncology, Tausig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: velchev@ccf.org.
          Article
          S0012-3692(17)30882-6
          10.1016/j.chest.2017.04.177
          28499515
          97d31678-8680-48ec-b778-9661cc85582e
          History

          Immunotherapy,Meta-analysis,Non-small cell lung cancer,Pneumonitis,immune-related adverse events

          Comments

          Comment on this article